SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (8224)4/30/2003 8:13:06 PM
From: Biomaven  Read Replies (2) | Respond to of 52153
 
Neurocrine didn't have to pay anything to Pfizer/Pharmacia as compensation for taking over the ED drug. Instead in addition the rights and the documentation they also got the funds to run the second proof-of-concept phase II trial. In effect they will be served a drug ready for phase III with no costs whatsoever. Amazing.

Very reminiscent of the drug (Tarceva) that OSIP got courtesy of the FTC during the WLA/PFE merger.

Maybe PFE just doles these out to its currently favored biotech...

Peter

P.S. They say anything about the ED drug? Its class has been bedeviled by side effects (nausea).



To: Icebrg who wrote (8224)4/30/2003 10:58:09 PM
From: rkrw  Read Replies (1) | Respond to of 52153
 
I was being somewhat facetious. What nbix has accomplished should serve as a model for all of biotech in how to build shareholder value and for biotech investors in what to look for in a biotech.

I'm curious if there may be indications in addition to ED. No doubt another opportunistic and shrewd move.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News